Analysts on Wall Street have fueled a Microsoft (MSFT) stock rally thanks to recent calls from top analysts on the market. Microsoft’s stock has risen 17.9% year-to-date, driven by strong demand for its Azure cloud and AI services. The company has sealed a new partnership with INBRAIN Neuroelectronics to bring its AI power into medicine.

INBRAIN is working on a line of neural technologies with graphene as a base, and is calling on Microsoft for its agentic artificial intelligence (AI) tools. Using Azure for a base, the INBRAIN platform will be able to learn and adapt to the individual patient. The news sent MSFT shares higher on Monday, with stock now up 20% YTD. Additionally, MSFT is trading near the top of its 52-week range and above its 200-day simple moving average.

“By collaborating with Microsoft, we’re combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems,” INBRAIN co-founder and CEO Carolina Aguilar noted. “This partnership brings us closer to a future where brain-computer interfaces don’t just decode or modulate, but truly understand and respond to the nervous system in real time, making the nervous system, the body OS.”

Microsoft (MSFT) is also up after the company began selling its Copilot AI chatbot through social media influencers. Microsoft launched the campaign to attract younger audiences and boost its position in the fast-growing AI industry. Microsoft’s consumer marketing leader, Yusuf Mehdi, said influencer marketing works better than advertising. “These collaborations show what Copilot can do in real life in ways people can relate to,” he said.

Analysts see potential for Microsoft’s stock to increase, with all major analysts rating it as “Outperform” or “Buy”. Price targets range from $600 to $650, indicating optimism about future growth compared to the current market price of $505.